Transplantation medicine

Ventris Announces Launch of Next Generation Biologic, Allocell® AF

Retrieved on: 
Wednesday, April 14, 2021
Transplantation medicine

Allocell AF is designed with broad, augmented bone fibers that maximize the surface area, allowing the fibers to better fill the defect site.

Key Points: 
  • Allocell AF is designed with broad, augmented bone fibers that maximize the surface area, allowing the fibers to better fill the defect site.
  • Each lot of Allocell AF undergoes an in vivo rat osteoinductive (OI) potential testing, which is the gold standard in verifying osteoinductivity of the demineralized allograft.
  • "The excellent hydration, handling, consistency and structural characteristics of Allocell AF give me the confidence that I will obtain successful patient outcomes.
  • "\n"The Allocell AF fiber technology is the latest addition to the Allocell family that was introduced to the market in 2019.

TheraCell Announces The First Surgical Uses Of Its Novel TheraFuze DBF® Fiber Bag™ For Graft Containment In Spinal Surgery

Retrieved on: 
Tuesday, April 6, 2021
Medical specialties, Articles, Clinical medicine, Transplantation medicine, Graft, Political corruption, Polymer, Dietary fiber

The Fiber Bag is an allograft alternative to the resorbable polymer mesh bag products that are currently on the market.

Key Points: 
  • The Fiber Bag is an allograft alternative to the resorbable polymer mesh bag products that are currently on the market.
  • "The Fiber Bag is the best graft containment solution I have ever used and the only one that is actually a significant graft in itself.
  • The Fiber Bag is part of TheraCell's comprehensive portfolio of TheraFuze DBF procedure-specific graft solutions, currently available in the United States directly through TheraCell.
  • TheraFuze DBF, TheraFuze DBF Fiber Bag, FiberLok, and The Bag That Is A Graft are trademarks of TheraCell, Inc.
    For more information on these products, please visit TheraCell's website .

eGenesis Expands Research Collaboration with Leading Academic Medical Center

Retrieved on: 
Thursday, April 1, 2021
Medical specialties, Clinical medicine, Transplantation medicine, Organ transplantation, Transplant rejection, Primate, Pancreatic islets

The expanded collaboration now includes preclinical research of gene-edited kidneys implanted in non-human primate (NHP) recipients, which builds on the original research collaboration for the implantation of the Companys gene-edited pancreatic islet cells in NHPs that began in 2020.

Key Points: 
  • The expanded collaboration now includes preclinical research of gene-edited kidneys implanted in non-human primate (NHP) recipients, which builds on the original research collaboration for the implantation of the Companys gene-edited pancreatic islet cells in NHPs that began in 2020.
  • Professor of Surgery in the School of Medicine, and Executive Director of the Duke Transplant Center, will lead the research.
  • Michael Curtis, Ph.D., President of Research & Development of eGenesis added, The Duke Medical team under Dr. Knechtles leadership is a leading transplant program with strong research capabilities in preventing organ rejection.
  • This collaboration will accelerate research and validation of our gene edited kidneys, leading to their evaluation in clinical trials.

15 RECELL® System Abstracts Accepted for Presentation at 53ʳᵈ Annual American Burn Association Meeting

Retrieved on: 
Tuesday, March 30, 2021
Medical specialties, Medicine, Clinical medicine, Transplantation medicine, Transfusion medicine, Tulane University, Burn center, Autotransplantation

The meeting, which will be held virtually April 7-9, 2021, annually brings together more than 2,000 multi-disciplinary burn care professionals from around the world.

Key Points: 
  • The meeting, which will be held virtually April 7-9, 2021, annually brings together more than 2,000 multi-disciplinary burn care professionals from around the world.
  • The acceptance and adoption of RECELL is reflected in these physician-initiated presentations, representing the collective experience of 20 burn centers.
  • Author: M Taylor, Tulane University School of Medicine, New Orleans, LA
    Autologous Skin Cell Suspension (ASCS) for the Treatment of Small (
  • Author: J Carter, University Medical Center Burn Center, New Orleans, LA
    Evaluating Real-World National and Regional Trends in Definitive Closure in US Burn Care: A Survey of US Burn Centers.

Worldwide Burn Care Industry to 2026 - by Type, End-users and Geography - ResearchAndMarkets.com

Retrieved on: 
Monday, March 29, 2021
Health, General Health, Medical specialties, Clinical medicine, Medicine, Plastic surgery, Graft, Surgery, Transplantation medicine, Skin grafting

Burn care products refers to all the types of products that are applied to the skin or the area of a human body after a burn.

Key Points: 
  • Burn care products refers to all the types of products that are applied to the skin or the area of a human body after a burn.
  • Moreover, an increase in skin grafting procedures further shows the positive outlook of the burn care market in the next five years.
  • The segmentation of the global burn care market has been done on the basis of type, end-user, and geography.
  • Geographically, the global burn care market has been distributed into North America, South America, Europe, Middle East and Africa, and the Asia Pacific.

Karmanos Cancer Institute receives a $325,372 grant from U CAN-CER VIVE Foundation

Retrieved on: 
Monday, March 29, 2021
Medical specialties, Branches of biology, Clinical medicine, Hematology, Stem cells, Transplantation medicine, Anatomical pathology, Biomarker, Cell biology, Hematopoietic stem cell transplantation, Karmanos, Lymphoma

"We take great pride in knowing that each dollar we raise goes directly toward cancer research here in the state of Michigan."

Key Points: 
  • "We take great pride in knowing that each dollar we raise goes directly toward cancer research here in the state of Michigan."
  • The U CAN-CER VIVE Foundation grant will fund the study Circulating Tumor DNA as a Predictive Biomarker of Outcomes of Autologous Stem Cell Transplantation in Relapsed Diffuse Large B cell Lymphoma, led by Dipenkumar Modi, M.D.
  • Karmanos Cancer Institute is headquartered in Detroit, with 15 locations throughout Michigan.
  • Karmanos cancer experts focus solely on cancer to prevent, detect and treat as well as eradicate all forms of cancer.

Medsenic Announces Positive Results of its Phase II Clinical Study with Arscimed® for the Treatment of Chronic Graft Versus Host Disease (cGvHD)

Retrieved on: 
Monday, March 29, 2021
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Medical specialties, Clinical medicine, Medicine, Hepatotoxins, Transplantation medicine, Immune system disorders, Graft-versus-host disease, Autoimmune diseases, Corticosteroid, Arsenic trioxide, Arsenic, Prednisone, Arscimed®, cGvHD, Medsenic

The study data validate the therapeutic potential of our product Arscimed, as a new selective immunosuppressive/anti-inflammatory drug for cGvHD.

Key Points: 
  • The study data validate the therapeutic potential of our product Arscimed, as a new selective immunosuppressive/anti-inflammatory drug for cGvHD.
  • The primary endpoint of this prospective Phase II multicentre, non-randomised study was the improvement of treatment response, i.e., complete or partial disease remission 6 months after GvHD diagnosis, with Arscimed in combination with prednisone with or without cyclosporine.
  • Over a 4-week period, 21 patients with moderate to severe chronic GvHD received as first-line treatment daily intravenous infusions of Medsenics arsenic trioxide drug.
  • This ability to eliminate the use of corticosteroids is a major advantage of arsenic trioxide treatment.

Magenta Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Conference

Retrieved on: 
Thursday, March 25, 2021
Health, General Health, Branches of biology, Biology, Life sciences, Biotechnology, Hematology, Hematopoietic stem cell transplantation, Surgical oncology, Transplantation medicine, Stem cell, Organ transplantation

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that Jason Gardner, D.Phil., President and Chief Executive Officer, is scheduled to participate in a panel discussion at the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Conference, being held virtually, on Thursday, April 1st, 2021.

Key Points: 
  • Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that Jason Gardner, D.Phil., President and Chief Executive Officer, is scheduled to participate in a panel discussion at the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Conference, being held virtually, on Thursday, April 1st, 2021.
  • The panel discussion, Key Advances in Solid Organ and Stem Cell Transplants - Expanding the Market and Moving Away from Lifelong Immunosuppression, will take place at 1:00 p.m.
  • A live webcast of the panel discussion can be accessed on the Magenta Therapeutics website at https://investor.magentatx.com/events-and-presentations .
  • Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases.

AOPO Proposes Changes to Trump-Era Rule to Save More Lives

Retrieved on: 
Tuesday, March 23, 2021
Organ donation, Medical specialties, Transplantation medicine, Clinical medicine, Organ transplantation, Organ procurement, Organ Donation (Deemed Consent) Act

The Association of Organ Procurement Organizations proposes changes to Trump-Era rule to save more lives.

Key Points: 
  • The Association of Organ Procurement Organizations proposes changes to Trump-Era rule to save more lives.
  • "Real patient lives hang in the balance so any policy changes must be carefully considered.
  • "Given the interdependent nature of the organ donation and transplantation system, we propose a collaborative effort which will save substantially more lives."
  • AOPO leads the nation's organ donation community through innovation, advocacy, and education to pursue the day when every donation opportunity results in lives saved.

Global Dental Bone Graft Substitute Market to 2024 - Trends, Forecast and Competitive Analysis - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 23, 2021
Dental, Health, Medical specialties, Clinical medicine, Medicine, Transplantation medicine, Oral and maxillofacial surgery, Bone grafting, Graft, Dentistry, Oral surgery

The "Dental Bone Graft Substitute Market Report: Trends, Forecast and Competitive Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dental Bone Graft Substitute Market Report: Trends, Forecast and Competitive Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The study includes the dental bone graft substitutes market size and forecast for the dental bone graft substitutes market through 2024, segmented by material, application, product, end use, and region.
  • Growth opportunities: Analysis on growth opportunities in different applications and regions for dental bone graft substitutes in the dental bone graft substitutes market.
  • Strategic analysis: This includes M&A, new product development, and competitive landscape for, dental bone graft substitutes in the dental bone graft substitutes market.